ANIK — Anika Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Annual income statement for Anika Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	106	115	130	148	156
Cost of Revenue
Gross Profit	74.3	85.9	69	82.9	93.6
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	83.8	80.4	159	145	176
Operating Profit	21.7	34.2	-28.3	2.62	-19.4
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	23.2	36.1	-28.6	2.43	-18.7
Provision for Income Taxes
Net Income After Taxes	18.7	27.2	-24	4.13	-14.9
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	18.7	27.2	-24	4.13	-14.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	18.7	27.2	-24	4.13	-14.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.27	1.89	0.257	0.57	-1.02

Discover the metrics influencing Anika Therapeutics's share price